Bone and Joint Infection Market to 2016 - Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment

Summary

GBI Research, the leading business intelligence provider, has released its latest research “Bone and Joint Infection Market to 2016- Medical Imaging and PCR methods to Facilitate Early Diagnosis and Treatment”, which provides insights into bone and joint infections market sales and price forecasts until 2016. The report also examines the global bone and joint infections therapies treatment usage patterns. In addition, the geographical distribution of bone and joint infections therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report provides an in-depth analysis of the top three bone and joint infections market therapeutic indications, which are prosthetic joint infection, osteomyelitis and septic arthritis. Furthermore, it also includes the market forecasts and treatment usage patterns of these these therapeutic indications. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving bone and joint infections therapies is also presented.

In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by the GBI Research team of experts.

GBI Research analysis showed that the global bone and joint infections market was estimated at $0.7 billion in 2009, with a year-on-year growth rate of 6.4% between 2001 and 2009. GBI Research forecasts that the market will grow at a Compound Annual Growth Rate (CAGR) of 8.1% between 2009 and 2016 to record a sales value of $1.2 billion. The patent expiry of two of the branded drugs by 2016 is expected to make way for the entry of generics.

Many of the major pharmaceutical companies such as GlaxoSmithKline, Hoffman-La Roche, Ranbaxy, Bayer AG, Teva Pharmaceuticals, Eli Lilly, Pfizer, Hospira, Leo pharma A/S, App pharmaceuticals and Abbott are either entering or expanding into the market. They are collaborating with or acquiring small and medium-sized enterprises (SME) biotechnology companies. The main factor that is driving the big pharmaceutical companies towards the bone and joint infections therapeutics market is the increasing market for infectious diseases mainly indications related to infections caused due to staphylococcus species. As staphylococcus aureus is one of the major causative organisms for infectious diseases. Bone and joint infections is one of the most common infectious diseases.

Scope

- Data and analysis on the bone and joint infections market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the bone and joint infections market from 2001 to 2009, with forecasts to 2016.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Key drivers and restraints that have had a significant impact on the market.
- The top companies benchmarking in the bone and joint infections therapeutics market The key companies studied in this report are GlaxoSmithKline, Hoffman-La Roche, Ranbaxy, Bayer AG, Teva Pharmaceuticals, Eli Lilly, Pfizer, Hospira, Leo pharma A/S, App pharmaceuticals and Abbott.
- Key M&A activities and Licensing Agreements that took place in 2008 and 2009 in the bone and joint infections market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Table Of Contents

1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 8
2 Bone and Joint Infecmtion Market to 2016: Introduction 10
2.1 GBI Research Report Guidance 10
3 Bone and Joint Infection Market to 2016: Market Overview 11
3.1 Introduction 11
3.2 Revenue Forecasts for the Global Bone and Joint Infection Market 11
3.2.1 Revenue 11
3.2.2 Annual Cost of Treatment (ACT) 13
3.2.3 Treatment Usage Patterns 14
4 Bone and Joint Infection Market to 2016: Geographical Landscape 20
4.1 Revenue Analysis by Geography 20
4.2 The US 22
4.2.1 Revenue 22
4.2.2 Annual Cost of Treatment (ACT) 23
4.2.3 Treatment Usage Patterns 24
4.3 Top Five Countries in Europe 29
4.3.1 Revenue 29
4.3.2 Annual Cost of Treatment (ACT) 30
4.3.3 Treatment Usage Patterns 31
4.4 Japan 37
4.4.1 Revenue 37
4.4.2 Annual Cost of Treatment (ACT) 38
4.4.3 Treatment Usage Patterns 39
5 Bone and Joint Infection Market to 2016: Therapeutic Landscape 45
5.1 Prosthetic Joint Infections Therapeutics Market 45
5.1.1 Introduction 45
5.1.2 Revenue 46
5.1.3 Annual Cost of Treatment 47
5.1.4 Treatment Usage Patterns 48
5.1.5 Drivers and Barriers for the Prosthetic Joint Infections Therapeutics Market 54
5.1.6 Drivers for the Prosthetic Joint Infections Therapeutics Market 54
5.1.7 Barriers for the Prosthetic Joint Infections Therapeutics Market 55
5.1.8 Opportunity and Unmet Need 55
5.2 Osteomyelitis Therapeutics Market 55
5.2.1 Introduction 55
5.2.2 Revenue 56
5.2.3 Annual Cost of Treatment (ACT) 57
5.2.4 Treatment Usage Patterns 58
5.2.5 Drivers and Barriers for the Osteomyelitis Therapeutics Market 64
5.2.6 Drivers for the Osteomyelitis Therapeutics Market 64
5.2.7 Barriers for the Osteomyelitis Therapeutics Market 65
5.2.8 Opportunity and Unmet Need 65
5.3 Septic Arthritis Therapeutics Market 65
5.3.1 Introduction 65
5.3.2 Revenue 66
5.3.3 Annual Cost of Treatment (ACT) 67
5.3.4 Treatment Usage Patterns 68
5.3.5 Drivers and Barriers for the Septic Arthritis Therapeutics Market 74
5.3.6 Drivers for the Septic Arthritis Therapeutics Market 74
5.3.7 Barriers for the Septic Arthritis Therapeutics market 75
5.3.8 Opportunity and Unmet Need 75
6 Bone and Joint Infection Market to 2016: Pipeline Analysis 76
6.1 Introduction 76
6.1.1 Research and Development Pipeline-Bone and Joint Infection 76
6.2 Profiles of Key Late Stage Drugs in the Bone and Joint Infection Market 81
6.2.1 Pagibaximab 81
6.2.2 TAKSTA 81
6.2.3 V710 82
6.2.4 Ceftobiprole 82
6.2.5 Teflaro 84
6.2.6 Torezolid 86
6.2.7 Rotarix + Infanrix + Pediarix + GSK 208108 + Prevnar 13 87
7 Bone and Joint Infection Market to 2016: Competitive Landscape 89
7.1 Overview 89
7.2 Competitive Profiling 89
7.2.1 Sandoz GmbH 89
7.2.2 GlaxoSmithKline 91
7.2.3 F. Hoffmann-La Roche Ltd. 93
7.2.4 Ranbaxy 94
7.2.5 Bayer AG 96
7.2.6 Teva Pharmaceutical Industries Limited 99
7.2.7 Eli Lilly and Company 102
7.2.8 Pfizer Inc. 104
7.2.9 Hospira, Inc. 106
7.2.10 LEO Pharma A/S 107
7.2.11 APP Pharmaceuticals, Inc. 108
7.2.12 Abbott Laboratories 109
8 Bone and Joint Infection Market to 2016: MandA Landscape 111
8.1 Global Bone and Joint Infection Market 111
8.1.1 Overview: Deals by Type 111
8.2 Mergers and Acquisitions 112
8.2.1 Overview 112
8.2.2 Durata Therapeutics Acquires Vicuron Pharmaceuticals 112
8.2.3 Aptuit Acquires Medicines Research Centre from GlaxoSmithKline 112
8.2.4 Hospira Acquires Pliva 113
8.3 Licensing Agreements 114
8.3.1 GlaxoSmithKline (GSK) and Isis Pharmaceuticals 114
8.3.2 Sanofi-aventis and Novozymes 114
8.3.3 Deals by Geography 114
8.3.4 Deals by Year 115
9 Bone and Joint Infection Market to 2016: Appendix 116
9.1 Market Definition 116
9.2 Abbreviations 116
9.3 Research Methodology 117
9.3.1 Coverage 117
9.3.2 Secondary Research 117
9.3.3 Forecasting 118
9.3.4 Primary Research 120
9.3.5 Expert Panels 120
9.4 Contact Us 120
9.5 Disclaimer 121
9.6 Sources 121

1.1 List of Tables
Table 1: Bone and Joint Infection Market, Global, Revenue ($bn), 2001-2009 12
Table 2: Bone and Joint Infection Market, Global, Revenue Forecasts ($bn), 2009-2016 12
Table 3: Bone and Joint Infection Market, Global, Annual Cost of Treatment ($), 2001-2009 13
Table 4: Bone and Joint Infection Market, Global, Annual Cost of Treatment ($), 2009-20016 13
Table 5: Bone and Joint Infection Market, Global, Treatment Usage Patterns (thousands), 2001 -2009 14
Table 6: Bone and Joint Infection Market, Global, Treatment Usage Patterns (thousands), 2009 -2016 15
Table 7: Bone and Joint Infection Market, Global, Diseased Population (thousands) 2001-2009 16
Table 8: Bone and Joint Infection Market, Global, Diseased Population (thousands) 2009-2016 16
Table 9: Bone and Joint Infection Market, Global, Treatment Seeking Population (thousands) 2001-2009 17
Table 10: Bone and Joint Infection Market, Global, Treatment Seeking Population (thousands) 2009-2016 17
Table 11: Bone and Joint Infection Market, Global, Diagnosed Population (thousands), 2001-2009 18
Table 12: Bone and Joint Infection Market, Global, Diagnosed Population (thousands) 2009-2016 18
Table 13: Bone and Joint Infection Market, Global, Prescription Population (thousands) 2001-2009 19
Table 14: Bone and Joint Infection Market, Global, Prescription Population (thousands) 2009-2016 19
Table 15: Bone and Joint Infection Market, Global, Revenue Analysis by Geography ($m), 2001-2009 21
Table 16: Bone and Joint Infection Market, Global, Revenue Analysis by Geography ($m), 2009-2016 21
Table 17: Bone and Joint Infection Market, The US, Revenue ($m), 2001-2009 22
Table 18: Bone and Joint Infection Market, The US, Revenue Forecast ($m), 2009-2016 22
Table 19: Bone and Joint Infection Market, The US, Annual Cost of Treatment($), 2001-2009 23
Table 20: Bone and Joint Infection Market, The US, Annual Cost of Treatment($), 2009-2016 23
Table 21: Bone and Joint Infection Market, The US, Treatment Usage Patterns, 2001-2009 24
Table 22: Bone and Joint Infection Market, The US, Treatment Usage Patterns, 2009-2016 24
Table 23: Bone and Joint Infection Market, The US, Diseased Population (thousands) 2001-2009 25
Table 24: Bone and Joint Infection Market, The US, Diseased Population (thousands) 2009-2016 25
Table 25: Bone and Joint Infection Market, The US, Treatment Seeking Population (thousands) 2001-2009 26
Table 26: Bone and Joint Infection Market, The US, Treatment Seeking Population (thousands) 2009-2016 26
Table 27: Bone and Joint Infection Market, The US, Diagnosed Population (thousands) 2001-2009 27
Table 28: Bone and Joint Infection Market, The US, Diagnosed Population (thousands) 2009-2016 27
Table 29: Bone and Joint Infection Market, The US, Prescription Population (thousands) 2001-2009 28
Table 30: Bone and Joint Infection Market, The US, Prescription Population (thousands) 2009-2016 28
Table 31: Bone and Joint Infection Market, Top Five countries in Europe, Revenue ($m), 2001-2009 29
Table 32: Bone and Joint Infection Market, Top Five countries in Europe, Revenue Forecasts ($m), 2009-2016 29
Table 33: Bone and Joint Infection Market, Top Five Countries in Europe, Annual Cost of Treatment ($), 2001-2009 30
Table 34: Bone and Joint Infection Market, Top Five Countries in Europe, Annual Cost of Treatment ($), 2009-2016 30
Table 35: Bone and Joint Infection Market, Top Five Countries in Europe, Treatment Usage Patterns (thousands), 2001-2009 31
Table 36: Bone and Joint Infection Market, Top Five Countries in Europe, Treatment Usage Patterns (thousands), 2009-2016 32
Table 37: Bone and Joint Infection Market, Top Five Countries in Europe, Diseased Population (thousands) 2001-2009 33
Table 38: Bone and Joint Infection Market, Top Five Countries in Europe, Diseased Population (thousands) 2009-2016 33
Table 39: Bone and Joint Infection Market, Top Five Countries in Europe, Treatment Seeking Population (thousands) 2001-2009 34
Table 40: Bone and Joint Infection Market, Top Five Countries in Europe, Treatment Seeking Population (thousands) 2009-2016 34
Table 41: Bone and Joint Infection Market, Top Five Countries in Europe, Diagnosed Population (thousands) 2001-2009 35
Table 42: Bone and Joint Infection Market, Top Five Countries in Europe, Diagnosed Population (thousands) 2009-2016 35
Table 43: Bone and Joint Infection Market, Top Five Countries in Europe, Prescription Population (thousands) 2001-2009 36
Table 44: Bone and Joint Infection Market, Top Five Countries in Europe, Prescription Population (thousands) 2009-2016 36
Table 45: Bone and Joint Infection Market, Japan, Revenue ($m), 2001-2009 37
Table 46: Bone and Joint Infection Market, Japan, Revenue ($m), 2009-2016 37
Table 47: Bone and Joint Infection Market, Japan, Annual Cost of Treatment ($), 2001-2009 38
Table 48: Bone and Joint Infection Market, Japan, Annual Cost of Treatment($), 2009-2016 38
Table 49: Bone and Joint Infection Market, Japan, Treatment Usage Patterns (thousands), 2001-2009 39
Table 50:Bone and Joint Infection Market, Japan, Treatment Usage Patterns (thousands), 2009-2016 40
Table 51: Bone and Joint Infection Market, Japan, Diseased Population (thousands) 2001-2009 41
Table 52: Bone and Joint Infection Market, Japan, Diseased Population (thousands) 2009-2016 41
Table 53: Bone and Joint Infection Market, Japan, Treatment Seeking Population (thousands) 2001-2009 42
Table 54: Bone and Joint Infection Market, Japan, Treatment Seeking Population (thousands) 2009-2016 42
Table 55: Bone and Joint Infection Market, Japan, Diagnosed Population (thousands) 2001-2009 43
Table 56: Bone and Joint Infection Market, Japan, Diagnosed Population (thousands) 2009-2016 43
Table 57: Bone and Joint Infection Market, Japan, Prescription Population (thousands) 2001-2009 44
Table 58: Bone and Joint Infection Market, Japan, Prescription Population (thousands) 2009-2016 44
Table 59: Prosthetic Joint Infections Therapeutics Market, Global, Revenue ($m), 2001-2009 46
Table 60: Prosthetic Joint Infections Therapeutics Market, Global, Revenue Forecast ($m), 2009-2016 46
Table 61: Prosthetic Joint Infections Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009 47
Table 62: Prosthetic Joint Infections Therapeutics Market, Global, Annual Cost of Treatment($), 2009-2016 47
Table 63: Prosthetic Joint Infections Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2001-2009 48
Table 64: Prosthetic Joint Infection Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2009-2016 49
Table 65: Prosthetic Joint Infections Therapeutics Market, Global, Diseased Population (thousands), 2001-2009 50
Table 66: Prosthetic Joint Infections Therapeutics Market, Global, Diseased Population (thousands), 2009-2016 50
Table 67: Prosthetic Joint Infections Therapeutics Market, Global, Treatment Seeking Population (thousands), 2001-2009 51
Table 68: Prosthetic Joint Infections Therapeutics Market, Global, Treatment Seeking Population (thousands), 2009-2016 51
Table 69: Prosthetic Joint Infections Therapeutics Market, Global, Diagnosed Population (thousands), 2001-2009 52
Table 70: Prosthetic Joint Infections Therapeutics Market, Global, Diagnosed Population (thousands), 2009-2016 52
Table 71: Prosthetic Joint Infections Therapeutics Market, Global, Prescription Population (thousands), 2001-2009 53
Table 72: Prosthetic Joint Infections Therapeutics Market, Global, Prescription Population (thousands), 2009-2016 53
Table 73: Osteomyelitis Therapeutics Market, Global, Revenue ($m), 2001-2009 56
Table 74: Osteomyelitis Therapeutics Market, Global, Revenue Forecast ($m), 2009-2016 56
Table 75: Osteomyelitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009 57
Table 76: Osteomyelitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-2016 57
Table 77: Osteomyelitis Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2001-2009 58
Table 78: Osteomyelitis Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2009-2016 59
Table 79: Osteomyelitis Therapeutics Market, Global, Diseased Population (thousands), 2001-2009 60
Table 80: Osteomyelitis Therapeutics Market, Global, Diseased Population (thousands), 2009-2016 60
Table 81: Osteomyelitis Therapeutics Market, Global, Treatment Seeking Population (thousands), 2001-2009 61
Table 82: Osteomyelitis Therapeutics Market, Global, Treatment Seeking Population (thousands), 2009-2016 61
Table 83: Osteomyelitis Therapeutics Market, Global, Diagnosed Population (thousands),2001-2009 62
Table 84: Osteomyelitis Therapeutics Market, Global, Diagnosed Population (thousands),2009-2016 62
Table 85: Osteomyelitis Therapeutics Market, Global, Prescription Population (thousands), 2001-2009 63
Table 86: Osteomyelitis Therapeutics Market, Global, Prescription Population (thousands), 2009-2016 63
Table 87: Septic Arthritis Therapeutics Market, Global, Revenue ($m), 2001-2009 66
Table 88: Septic Arthritis Therapeutics Market, Global, Revenue Forecast ($m), 2009-2016 66
Table 89: Septic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009 67
Table 90: Septic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-2016 67
Table 91: Septic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2001-2009 68
Table 92: Septic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2009-2016 69
Table 93: Septic Arthritis Therapeutics Market, Global, Diseased Population (thousands), 2001-2009 70
Table 94: Septic Arthritis Therapeutics Market, Global, Diseased Population (thousands), 2009-2016 70
Table 95: Septic Arthritis Therapeutics Market, Global, Treatment Seeking Population (thousands), 2001-2009 71
Table 96: Septic Arthritis Therapeutics Market, Global, Treatment Seeking Population (thousands), 2009-2016 71
Table 97: Septic Arthritis Therapeutics Market, Global, Diagnosed Population (thousands), 2001-2009 72
Table 98: Septic Arthritis Therapeutics Market, Global, Diagnosed Population (thousands), 2009-2016 72
Table 99: Septic Arthritis Therapeutics Market, Global, Prescription Population (thousands), 2001-2009 73
Table 100:Septic Arthritis Therapeutics Market, Global, Prescription Population (thousands), 2009-2016 73
Table 101:Bone and Joint Infection Market, Pipeline, Discovery Stage Molecules, 2010 76
Table 102:Bone and Joint Infection Market, Pipeline, Preclinical Molecules, 2010 77
Table 103:Bone and Joint Infection Market, Pipeline, Phase I Molecules, 2010 78
Table 104:Bone and Joint Infection Market, Pipeline, Phase II Molecules, 2010 79
Table 105:Bone and Joint Infection Market, Pipeline, Phase II Molecules, 2010 80
Table 106:Bone and Joint Infection Market, Pipeline, Filed Molecules, 2010 80
Table 107:Bone and Joint Infection Market, Global, Major MandA Deals, 2008-2010 113

1.2 List of Figures
Figure 1: Bone and Joint Infection Market, Global, Revenue Forecasts ($bn), 2001-2016 11
Figure 2: Bone and Joint Infection Market, Global, Annual Cost of Treatment ($), 2001-2016 13
Figure 3: Bone and Joint Infection Market, Global, Treatment Usage Patterns (thousands), 2001-2016 14
Figure 4: Bone and Joint Infection Market, Global, Diseased Population (thousands) 2001-2016 16
Figure 5: Bone and Joint Infection Market, Global, Treatment Seeking Population (thousands) 2001-2016 17
Figure 6: Bone and Joint Infection Market, Global, Diagnosed Population (thousands) 2001-2016 18
Figure 7: Bone and Joint Infection Market, Global, Prescription Population (thousands) 2001-2016 19
Figure 8: Bone and Joint infections Market, Global, Revenue Analysis by Geography ($bn), 2001-2016 20
Figure 9: Bone and Joint Infection Market, The US, Revenue Forecasts ($m), 2001-2016 22
Figure 10: Bone and Joint Infection Market, The US, Annual Cost of Treatment ($), 2001-2016 23
Figure 11: Bone and Joint Infection Market, The US, Treatment Usage Patterns, 2001-2016 24
Figure 12: Bone and Joint Infection Market, The US, Diseased Population (thousands) 2001-2016 25
Figure 13: Bone and Joint Infection Market, The US, Treatment Seeking Population (thousands) 2001-2016 26
Figure 14: Bone and Joint Infection Market, The US, Diagnosed Population (thousands) 2001-2016 27
Figure 15: Bone and Joint Infection Market, The US, Prescription Population (thousands) 2001-2016 28
Figure 16: Bone and Joint Infection Market, Top Five countries in Europe, Revenue Forecasts ($m), 2001-2016 29
Figure 17: Bone and joint infections Therapeutics Market, Top Five Countries in Europe, Annual Cost of Treatment ($), 2001-2016 30
Figure 18: Bone and Joint Infection Market, Top Five Countries in Europe, Treatment Usage Patterns (thousands), 2001-2016 31
Figure 19: Bone and Joint Infection Market, Top Five Countries in Europe, Diseased Population (thousands), 2001-2016 33
Figure 20: Bone and Joint Infection Market, Top Five Countries in Europe, Treatment Seeking Population (thousands) 2001-2016 34
Figure 21: Bone and Joint Infection Market, Top Five Countries in Europe, Diagnosed Population (thousands) 2001-2016 35
Figure 22: Bone and Joint Infection Market, Top Five Countries in Europe, Diagnosed Population (thousands) 2001-2016 36
Figure 23: Bone and Joint Infection Market, Japan, Revenue Forecast ($m), 2001-2016 37
Figure 24: Bone and Joint Infection Market, Japan, Annual Cost of Treatment ($), 2001-2016 38
Figure 25: Bone and Joint Infection Market, Japan, Treatment Usage Patterns (thousands), 2001-2016 39
Figure 26: Bone and Joint Infection Market, Japan, Diseased Population (thousands) 2001-2016 41
Figure 27: Bone and Joint Infection Market, Japan, Treatment Seeking Population (thousands) 2001-2016 42
Figure 28: Bone and Joint Infection Market, Japan, Diagnosed Population (thousands) 2001-2016 43
Figure 29: Bone and Joint Infection Market, Japan, Prescription Population (thousands) 2001-2016 44
Figure 30: Prosthetic Joint Infections Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016 46
Figure 31: Prosthetic Joint Infections Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 47
Figure 32: Prosthetic Joint Infections Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2001-2016 48
Figure 33: Prosthetic Joint Infections Therapeutics Market, Global, Diseased Population (thousands), 2001-2016 50
Figure 34: Prosthetic Joint Infections Therapeutics Market, Global, Treatment Seeking Population (thousands), 2001-2016 51
Figure 35: Prosthetic Joint Infections Therapeutics Market, Global, Diagnosed Population (thousands), 2001-2016 52
Figure 36: Prosthetic Joint Infections Therapeutics Market, Global, Prescription Population (thousands), 2001-2016 53
Figure 37: Prosthetic Joint Infections Therapeutics, Market Drivers and Barriers, 2009-2016 54
Figure 38: Osteomyelitis Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016 56
Figure 39: Osteomyelitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 57
Figure 40: Osteomyelitis Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2001-2016 58
Figure 41: Osteomyelitis Therapeutics Market, Global, Diseased Population (thousands), 2001-2016 60
Figure 42: Osteomyelitis Therapeutics Market, Global, Treatment Seeking Population (thousands), 2001-2016 61
Figure 43: Osteomyelitis Therapeutics Market, Global, Diagnosed Population (thousands), 2001-2016 62
Figure 44: Osteomyelitis Therapeutics Market, Global, Prescription Population (thousands), 2001-2016 63
Figure 45: Osteomyelitis Therapeutics Market, Global, Market Drivers and Barriers, 2009-2016 64
Figure 46: Septic Arthritis Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016 66
Figure 47: Septic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 67
Figure 48: Septic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2001-2016 68
Figure 49: Septic Arthritis Therapeutics Market, Global, Diseased Population (thousands), 2001-2016 70
Figure 50: Septic Arthritis Therapeutics Market, Global, Treatment Seeking Population (thousands), 2001-2016 71
Figure 51: Septic Arthritis Therapeutics Market, Global, Diagnosed Population (thousands), 2001-2016 72
Figure 52: Septic Arthritis Therapeutics Market, Global, Prescription Population (thousands), 2001-2016 73
Figure 53: Septic Arthritis Therapeutics Market, Global, Market Drivers and Barriers, 2009-2016 74
Figure 54: Arthritis Therapeutics Market, Global, RandD Pipeline by Phase (%), 2010 76
Figure 55: SWOT Analysis of Sandoz GmbH 91
Figure 56: SWOT Analysis of GlaxoSmithKline 93
Figure 57: SWOT Analysis of F.Hoffmann-La Roche Ltd. 94
Figure 58: SWOT Analysis of Ranbaxy 96
Figure 59: SWOT Analysis of Bayer AG 98
Figure 60: SWOT Analysis of Teva Pharmaceutical Industries Limited 101
Figure 61: SWOT Analysis of Eli-lilly and Company 103
Figure 62: SWOT Analysis of Pfizer 106
Figure 63: SWOT Analysis of Hospira, Inc 107
Figure 64: SWOT Analysis of LEO Pharma A/S 108
Figure 65: SWOT Analysis of APP Pharmaceuticals, Inc. 109
Figure 66: SWOT Analysis of Abbott Laboratories 110
Figure 67: Bone and Joint Infection Market, Global, Deals by Type, 2008-2010 111
Figure 68: Bone and Joint Infection Market, Global, Major Deals By Geography, 2008-2010 114
Figure 69:Bone and Joint Infection Market, Global, Major Deals By Year, 2008-2010 115
Figure 70: GBI Research Market Forecasting Model 119

Companies Mentioned
Sandoz GmbH
GlaxoSmithKline
F. Hoffmann-La Roche Ltd.
Ranbaxy
Bayer AG
Teva Pharmaceutical Industries Limited
Eli Lilly and Company
Pfizer Inc.
Hospira, Inc.
LEO Pharma A/S
APP Pharmaceuticals, Inc.
Abbott Laboratories

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Diagnostics and Therapeutics for HIV: Global Markets

Diagnostics and Therapeutics for HIV: Global Markets

  • $ 6 650
  • Industry report
  • April 2014
  • by BCC Research

STUDY GOALS AND OBJECTIVES The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for products used in the treatment, testing ...

JAK and PI3K Signaling Pathway Markets

JAK and PI3K Signaling Pathway Markets

  • $ 6 650
  • Industry report
  • April 2014
  • by BCC Research

REPORT HIGHLIGHTS The global market for signal transduction therapies/inhibitors (JAK and PI3K) reached $173.5 million in 2012. This market is expected to grow to $464.5 million in 2013 and $2.2 billion ...

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.